Olmesartan Medoxomil
Pharmaceutical Premium
Pharmaceutical API

Olmesartan Medoxomil

High-purity pharmaceutical grade Olmesartan Medoxomil manufactured to meet stringent USP/EP specifications for pharmaceutical formulations and research applications. Our pharmaceutical grade material delivers exceptional purity and consistency for critical pharmaceutical manufacturing.

  • USP/EP Grade Specifications
  • High Purity (≥99.0%)
  • Comprehensive Analytical Testing
  • Regulatory Compliance Documentation
  • Pharmaceutical Manufacturing Grade
  • Quality Assurance Certified
Request Quote Technical Support

Technical Specifications

Chemical Formula: C29H30N6O6
CAS Number: 144689-63-4
EINECS Number: 603-205-1
Purity (HPLC): ≥99.0% (USP/EP Grade)
Physical State: White to off-white crystalline powder
Molecular Weight: 558.59 g/mol
Melting Point: 181-185°C
pH (1% solution): 6.0-8.0
Loss on Drying: ≤0.5%
Residue on Ignition: ≤0.1%
Heavy Metals: ≤10 ppm
Solubility: Practically insoluble in water
Storage Conditions: Store below 25°C, dry place
Shelf Life: 3 years from manufacture date
Packaging Options: 25kg, 50kg fiber drums

Applications

Antihypertensive Therapy
Blood Pressure Management
Tablet Formulations
ARB Medications
Cardiovascular Research
Cardiac Therapy
Renal Protection
Extended Release Formulations
Clinical Studies
Drug Development
Pharmacological Research
Regulatory Studies

Industry-Specific Grades

DRAVYOM offers specialized Olmesartan Medoxomil grades tailored for specific cardiovascular applications, ensuring optimal antihypertensive efficacy and regulatory compliance across diverse pharmaceutical formulations.

USP Grade (United States Pharmacopoeia)
Purity: ≥99.0% Water Content: ≤0.5% Heavy Metals: ≤10 ppm Application: FDA approved formulations
EP Grade (European Pharmacopoeia)
Purity: ≥99.0% Related Substances: ≤1.0% Residual Solvents: EP limits Application: European market compliance
Research Grade
Purity: ≥98.0% Activity: Verified Stability: Enhanced Application: Cardiovascular research
Extended Release Grade
Purity: ≥99.5% Particle Size: Controlled Flow Properties: Optimized Application: SR formulations

Quality Standards

DRAVYOM's Olmesartan Medoxomil is manufactured under stringent cGMP protocols, meeting international cardiovascular drug standards including USP, EP, and FDA guidelines for antihypertensive applications.

cGMP Manufacturing Standards
USP/EP Grade Specifications
≥99.0% HPLC Purity
Advanced Analytical Testing
Cardiovascular Efficacy Verified
Batch-to-Batch Consistency
Comprehensive COA Documentation
Controlled Storage & Shipping

Advanced Chemical Properties & Performance

Pharmaceutical Grade Olmesartan Medoxomil exhibits exceptional chemical properties essential for cardiovascular applications. Its potent ARB structure and superior stability characteristics ensure reliable performance in demanding antihypertensive formulations.

Molecular Properties
Molecular Weight: 558.59 g/mol
Molecular Formula: C29H30N6O6
LogP (Octanol/Water): 4.9
Solubility (Water): Practically insoluble
Physical Properties
Melting Point: 181-185°C
Appearance: White to off-white crystalline powder
Crystal Form: Anhydrous polymorphic Form I
Bulk Density: 0.35-0.45 g/cm³
Pharmaceutical Properties
Bioavailability: 26%
Protein Binding: 99%
Half-life: 13 hours
Mechanism: Angiotensin II receptor blockade
Quality Specifications
Purity (HPLC): ≥99.0%
Water Content: ≤0.5%
Related Substances: ≤1.0%
Heavy Metals: ≤10 ppm
Stability Properties
Shelf Life: 3 years (unopened)
Storage Temperature: 15-25°C
Light Sensitivity: Store in light-resistant containers
Moisture Sensitivity: Store in dry conditions

Performance Characteristics

Detailed performance metrics demonstrate Olmesartan Medoxomil superiority in cardiovascular applications with exceptional AT1 receptor blockade, blood pressure reduction, and therapeutic efficacy across diverse hypertension treatment protocols.

AT1 Receptor Blockade

Potent and selective angiotensin II receptor antagonism

Superior blood pressure control
Extended Duration

24-hour blood pressure control

Once-daily dosing convenience
Renal Protection

Nephroprotective effects in diabetic patients

Cardiovascular risk reduction
Dose Response

Linear dose-response relationship

Predictable therapeutic outcomes
Clinical Efficacy

FDA-approved for hypertension treatment

Proven cardiovascular benefits
Tablet Stability

Excellent formulation stability and compression

Superior pharmaceutical quality

Safety Information

Pharmaceutical active ingredient requiring careful handling protocols. Handle in controlled environments with appropriate ventilation systems. Use proper personal protective equipment and follow established safety protocols for cardiovascular APIs.

Cardiovascular Active
Controlled Handling Required
Specialized PPE Required

Storage & Handling

Store in tightly closed, light-resistant containers in a cool, dry place away from direct sunlight. Maintain controlled room temperature storage and ensure protection from moisture and humidity to preserve pharmaceutical quality and cardiovascular potency.

Controlled room temperature (15-25°C)
Protect from light
Light-resistant containers
Store in dry conditions

Chemical Mechanisms & Reaction Pathways

Olmesartan medoxomil functions as an angiotensin II receptor antagonist through selective AT1 receptor blockade, providing effective blood pressure reduction and cardiovascular protection with sustained therapeutic activity.

AT1 Receptor Blockade

Selective angiotensin II type 1 receptor antagonism

Vasodilation and blood pressure reduction
Prodrug Activation

Medoxomil ester hydrolysis to active olmesartan

Enhanced oral bioavailability
Cardioprotection

Reduced cardiac remodeling and vascular protection

Long-term cardiovascular benefits
Pharmacokinetic Profile

Long half-life enabling once-daily dosing

Sustained therapeutic coverage

Regulatory Compliance & Documentation

Comprehensive regulatory compliance ensures global pharmaceutical acceptance with complete documentation packages supporting international drug development and manufacturing requirements.

USP Specifications

United States Pharmacopeia pharmaceutical grade compliance

EP Standards

European Pharmacopoeia specifications and testing protocols

ICH Guidelines

International harmonized pharmaceutical development standards

Global Regulatory

Multi-regional pharmaceutical registration support

DMF Support

Drug Master File preparation and regulatory submission

GMP Compliance

Good Manufacturing Practice certified production

Technical Support & Value-Added Services

DRAVYOM's pharmaceutical development team provides comprehensive formulation support, analytical method development, and regulatory assistance to optimize Olmesartan Medoxomil performance in pharmaceutical applications.

Formulation Development
  • Tablet formulation optimization
  • Bioavailability enhancement
  • Stability improvement strategies
  • Combination drug development
Analytical Services
  • Method validation and transfer
  • Impurity profiling and identification
  • Stability testing programs
  • Dissolution testing support
Regulatory Support
  • Regulatory strategy development
  • Documentation preparation
  • Regulatory submission support
  • Global compliance guidance
Supply Solutions
  • Reliable supply chain management
  • Flexible packaging options
  • Emergency supply arrangements
  • Global distribution network

Environmental Impact & Sustainability

Our Olmesartan Medoxomil production emphasizes environmental responsibility through sustainable pharmaceutical manufacturing practices, waste minimization, and comprehensive environmental impact management.

Green Chemistry

Environmentally conscious synthesis with minimal waste

Water Management

Advanced wastewater treatment and recycling systems

Energy Efficiency

Optimized manufacturing processes with reduced energy consumption

Waste Reduction

Comprehensive waste minimization and disposal protocols

ISO 14001

Environmental management system certified production

Carbon Footprint

Reduced environmental impact through sustainable practices

Manufacturing Excellence & Quality Control

DRAVYOM's state-of-the-art pharmaceutical manufacturing facility employs advanced synthesis technology and continuous monitoring systems to ensure consistent Olmesartan Medoxomil quality and performance across all production batches.

GMP Production

Good Manufacturing Practice certified facility with controlled environments

Pharmaceutical-grade production standards
Quality Testing

Comprehensive analytical testing including potency and purity

HPLC, LC-MS, and pharmacopeial methods
Quality Systems

ISO 9001:2015 quality management with pharmaceutical compliance

Continuous improvement and validation protocols
Packaging Control

Controlled atmosphere packaging with moisture protection

Stability maintenance and protection systems

Market Applications & Performance Data

Comprehensive pharmaceutical data demonstrating Olmesartan Medoxomil effectiveness across diverse therapeutic applications with quantified performance metrics and clinical validation.

Pharmaceutical Manufacturing
Bioavailability: Enhanced by prodrug design Stability: 3+ years shelf life Purity: >99.5% pharmaceutical grade
Drug Development
Formulation Support: Antihypertensive products Regulatory Success: Global approvals achieved Innovation: Combination therapies
Clinical Applications
Efficacy: Proven antihypertensive activity Safety: Excellent cardiovascular safety Compliance: Once-daily dosing

DRAVYOM Competitive Advantages

Pharmaceutical Excellence

Consistently exceeds USP/EP specifications with pharmaceutical-grade quality and performance

Reliable Supply

Guaranteed availability with strategic inventory management and pharmaceutical-grade production

Development Expertise

Dedicated pharmaceutical team provides formulation development and regulatory support

Quality Assurance

Comprehensive documentation with pharmaceutical-grade certificates and regulatory compliance

Global Standards

International compliance with USP, EP, and ICH guidelines for worldwide acceptance

Partnership Approach

Collaborative relationships with pharmaceutical companies and custom development services